| Literature DB >> 28117477 |
Rafael Futoshi Mizutani1, Mário Terra-Filho1,2, Evelise Lima1, Carolina Salim Gonçalves Freitas1, Rodrigo Caruso Chate3, Ronaldo Adib Kairalla1,2, Regiani Carvalho-Oliveira4, Ubiratan Paula Santos1.
Abstract
OBJECTIVE: : To describe diagnostic and treatment aspects of hard metal lung disease (HMLD) and to review the current literature on the topic.Entities:
Mesh:
Substances:
Year: 2016 PMID: 28117477 PMCID: PMC5344095 DOI: 10.1590/S1806-37562016000000260
Source DB: PubMed Journal: J Bras Pneumol ISSN: 1806-3713 Impact factor: 2.624
Characteristics of the patients with hard metal lung disease.
| Characteristic | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|---|---|---|---|---|---|
| Age, years | 44 | 30 | 30 | 43 | 63 |
| Smoking | No | No | No | Former smoker | No |
| Occupation | Grinder operator | Grinder operator | Industrial tool sharpener | Industrial tool sharpener | Industrial tool maintenance technician |
| Duration of exposure, years | 25 | 6 | 8 | 6 | 12 |
| Chest HRCT findings | Extensive ground-glass opacities and poorly defined centrilobular micronodules, predominantly in the middle and upper lung fields. Pattern suggestive of subacute HP | Fine reticulation, ground-glass opacities, and traction bronchiolectasis, distributed symmetrically and mainly peripherally, predominantly in the lung bases | Interstitial micronodular infiltrates distributed in a perilymphatic pattern, predominantly in the upper lung fields | Ground-glass opacities, peripheral reticulation, and traction bronchiectasis and bronchiolectasis, predominantly in the lower lung fields | Fine reticulation, ground-glass opacities, traction bronchiectasis and bronchiolectasis, distributed peripherally, and an area of air trapping in the left lower lobe |
| BAL pattern | Multinucleated giant cells | Multinucleated giant cells | Multinucleated giant cells | Multinucleated giant cells | Lymphocytic |
| Type of biopsy | Surgical | Surgical | Transbronchial | Surgical | Surgical |
| Histological pattern of the biopsy specimen | DIP and cellular bronchiolitis | GIP | GIP | GIP | HP |
| EDS results | Cobalt + Tungsten + | Cobalt - Tungsten + | NA | NA | NA |
| Treatment | Corticosteroid therapy, azathioprine | Corticosteroid therapy | Corticosteroid therapy | Corticosteroid therapy, azathioprine, placement on a lung transplant list | Corticosteroid therapy |
| Patient course | Worsening | Improvement | Improvement | Death | Worsening |
DIP: desquamative interstitial pneumonia; GIP: giant cell interstitial pneumonia; HP: hypersensitivity pneumonitis; EDS: energy-dispersive X-ray fluorescence spectrometry; and NA: not assessed.
Figure 1HRCT scans. Case 2, before treatment initiation (Figures A and B): ground-glass opacities and parenchymal consolidations with some air bronchograms in both lungs, predominantly in the middle and upper lung fields, in a pattern similar to that of organizing pneumonia. Case 2, after treatment (Figures C and D): the pulmonary changes were significantly reduced, there now being subtle foci of ground-glass opacification, mild, poorly defined centrilobular nodules, and scattered linear opacities, bilaterally.
Figure 2HRCT scans. Case 3 (Figures A and B): micronodular opacities distributed in a perilymphatic pattern, predominantly in the middle and upper lung fields. Case 4 (Figures C and D): ground-glass opacities and foci of parenchymal consolidation, predominantly in the middle and upper lung fields, as well as mild peripheral reticulation with traction bronchiectasis and bronchiolectasis.
Course of lung function in the study subjects.a
| Variable | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | After 14m | Baseline | After 60m | Baseline | After 56m | Baseline | After 30m | Baseline | After 24m | |
| FVC, L | 4.17 (79%) | 3.74 (67%) | 2.85 (63%) | 2.88 (59%) | 3.47 (63%) | 4.12 (76%) | 2.22 (49%) | 1.76 (39%) | 2.81 (83%) | 2.33 (61%) |
| FEV1, L | 3.54 (83%) | 3.20 (73%) | 2.45 (65%) | 2.38 (60%) | 2.73 (60%) | 3.08 (68%) | 2.09 (56%) | 1.70 (46%) | 2.32 (86%) | 1.94 (69%) |
| FEV1/FVC | 0.85 | 0.86 | 0.86 | 0.83 | 0.81 | 0.75 | 0.94 | 0.94 | 0.82 | 0.83 |
| TLC, L | NA | 5.57 (75%) | 4.31 (68%) | 5.11 (83%) | 5.19 (66%) | 5.89 (75%) | 3.80 (56%) | NA | 4.07 (65%) | 4.06 (65%) |
| RV, L | NA | 1.84 (91%) | 1.56 (96%) | 2.09 (142%) | 1.47 (79%) | 1.83 (98%) | 1.54 (77%) | NA | 1.29 (54%) | 1.67 (76%) |
| DLCO, mL/min/mmHg | NA | NA | 22.76 (72%) | 28.89 (106%) | 32.44 (93%) | 43.25 (107%) | 6.15 (20%) | NA | 19.39 (67%) | 11.29 (39%) |
m: months; and NA: not assessed. aPercent predicted values calculated for the Brazilian population according to Neder et al.
Figure 3BAL specimen containing macrophages, neutrophils, and lymphocytes, as well as multinucleated giant cells (Papanicolaou stain; magnification, ×400).
Figure 4Histological analysis of a lung biopsy specimen. Respiratory bronchiole stripped of its lining epithelium, filled with multinucleated giant cells (arrow), also observed in the adjacent alveoli, which are covered by metaplastic columnar epithelium (H&E; magnification, ×200).